Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Active-specific immunotherapy; B7-H4; Dendritic cell vaccine; Glioblastoma multiforme; IDH; TERT
Dendritic cell (DC)-based vaccination is a promising approach for active-specific immunotherapy, but is currently of limited efficacy. The safety and effectiveness of a DC vaccine (DCV) loaded with glioblastoma stem cell-like (GSC) antigens was assessed in glioblastoma multiforme (GBM) patients. In this double-blind, placebo-controlled phase II clinical trial, 43 GBM patients were randomized after surgery at a 1:1 ratio to receive either DCV (n = 22) or normal saline placebo (n = 21). Overall survival (OS) and progression-free survival (PFS) were analysed. Participants were stratified into different molecular subgroups based on the mutation (MT) status of isocitrate dehydrogenase (IDH1/2) and telomerase reverse transcriptase (TERT). Plasma cytokine levels, tumor-infiltrating lymphocyte numbers and immune co-inhibitory molecules PD-L1 and B7-H4 were also assessed. Multivariate Cox regression analysis revealed that DCV treatment significantly prolonged OS (p = 0.02) after adjusting for IDH1 and TERT promoter MT and B7-H4 expression, primary vs recurrent GBM. Among IDH1
Yao, Yu; Luo, Feifei; Tang, Chao; Chen, Dikang; Qin, Zhiyong; Hua, Wei; Xu, Ming; Zhong, Ping; Yu, Shuangquan; Chen, Di; Ding, Xiaojie; Zhang, Yi; Zheng, Xiujuan; Yang, Jiao; Qian, Jiawen; Deng, Yuting; Hoon, Dave S B; Hu, Jian; Chu, Yiwei; and Zhou, Liangfu, "Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial." (2018). Journal Articles and Abstracts. 609.